GlobalData on MSN1d
GSK’s combo therapy trial for advanced ovarian cancer meets primary endpointGSK has reported that the double-blind, randomised Phase III FIRST-ENGOT-OV44 trial of Zejula (niraparib) and Jemperli ...
Perhaps PD-1 inhibitors just aren’t for ovarian cancer after all. | Merck's and GSK's similar overall survival setbacks ...
Zacks.com on MSN7d
GSK Gets CHMP Nod for Expanded Use of HIV Combo & JemperliGSK plc’s GSK HIV subsidiary, ViiV Healthcare announced that the Europe Medicines Agency’s (“EMA”) Committee for Medicinal ...
First approved in 2021, Jemperli has now become a cornerstone of GSK’s cancer business, earning more than $160 million in the ...
The Wall Street Journal on MSN8d
GSK’s Cancer Drug Jemperli Moves a Step Closer to European Marketing PermissionIn one of the final steps before a marketing authorization decision by the European Medicines Agency, it recommended ...
Jemperli combo met its primary endpoint in a trial investigating the drugs in first-line advanced ovarian cancer, but missed ...
Approximately 121,000 people are diagnosed with primary advanced or recurrent endometrial cancer each year in Europe ...
UK pharma major GSK today released mixed headline results from the FIRST-ENGOT-OV44 Phase III trial evaluating Zejula ...
GSK (GSK) announced headline results from the FIRST-ENGOT-OV44 phase III trial evaluating Zejula and Jemperli in first line advanced ovarian cancer. The trial met its primary endpoint of PFS ...
GSK’s FIRST-ENGOT-OV44 phase III clinical trial of Zejula and Jemperl in first line advanced ovarian cancer meets primary endpoint: London Saturday, December 21, 2024, 09:00 Hrs ...
GSK (GSK) announced that the US Food and Drug Administration, FDA, has granted Breakthrough Therapy Designation, BTD, for ...
GSK plc (GSK, GSK.L) reported headline results from the FIRST-ENGOT-OV44 phase III trial evaluating Zejula and Jemperli in first line ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback